drugset

drugset / Trial / NCT05813795

A Phase 3 Study to Evaluate the Efficacy of XW003 in Adults With Overweight or Obesity

NCT05813795 ↗

Phase 3 Completed 664 enrolled Hangzhou Sciwind Biosciences Co., Ltd.

RandomizedParallel-groupTriple-blindTreatment

Summary

The aim of the study is to evaluate the efficacy and safety of XW003 versus placebo in adults with overweight or obesity

Timeline

Start: 2023-04-05
Primary completion: 2024-06-20
Completion: 2024-10-10

Publications

Ji L, Gao L, Xue H, Tian J, Wang K, Jiang H, Huang C, Lian Q, Yuan M, Gao G, Lu Y, Han J, Fu W, Wang H, Zhang Y, Shi X, Wen B, Shi B, Hu W, Guo T, Xing Y, Li Y, Li Q, Zheng Q, Yang M, Ning J, Guo M, Li Y, Pan H. Efficacy and safety of a biased GLP-1 receptor agonist ecnoglutide in adults with overweight or obesity: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Diabetes Endocrinol. 2025 Sep;13(9):777-789. doi: 10.1016/S2213-8587(25)00141-X. Epub 2025 Jun 21.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Ecnoglutide	Protein / enzyme biologic	1.2 mg	Subcutaneous
Subject	Ecnoglutide	Protein / enzyme biologic	1.8 mg	Subcutaneous
Subject	Ecnoglutide	Protein / enzyme biologic	2.4 mg	Subcutaneous

Indications

No indication recorded.